Latest News


Each news article below shows only part of the news story. To view the full story, click on Read More below the story. 

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 
  • December 02, 2019 12:34 PM | Becca Liebers (Administrator)

    Journal of the American Academy of Physician Assistants: December 2019 - Volume 32 - Issue 12 - p 11–12

    Gajarawala, Shilpa N. DMSc, MPAS, PA-C; Wood, Tiffany A. BSHS; Stanton, Amanda P. MHS, PA-C

    ABSTRACT In small clinical trials, dehydroepiandrosterone (DHEA) has been found to relieve symptoms associated with postmenopausal conditions and infertility in women. DHEA may provide a cost-effective alternative to typical hormone therapies. Because of a lack of long-term and large-scale studies, only intravaginal DHEA supplementation is approved and recommended for treatment. Further investigation of DHEA supplementation is needed and encouraged to determine its safety and effectiveness.

    AAPA Members can view Full text articles for FREE. Not a Member? Join today!

  • November 21, 2019 1:30 PM | Becca Liebers (Administrator)

    Washington, D.C. – Ted L. Anderson, MD, PhD, president of the American College of Obstetricians and Gynecologists (ACOG), issued the following statement regarding the vote out of the House Energy and Commerce Committee on H.R. 4995 and H.R. 4996: 

    “ACOG applauds the House Energy and Commerce Committee for advancing H.R. 4995 and H.R. 4996. The committee took a giant step toward eliminating preventable maternal deaths with these two critically important bills that will improve maternal health outcomes and build upon legislation passed last year.

    “These bills include ACOG’s top legislative priorities in the “Momnibus,” a collection of U.S. House and Senate bills aimed at addressing the maternal mortality crisis. Specifically, H.R. 4995 and H.R. 4996 will 

    • help hospitals and maternity care providers implement clinically proven best practices,
    • incentivize states to continue Medicaid or CHIP coverage for women for one year after delivery,
    • increase access to maternity care in rural and underserved areas,
    • work to eliminate racial and ethnic disparities in maternal health, and
    • provide support for perinatal quality collaboratives.

    “Typically, women lose Medicaid coverage 60 days after delivery. This legislation would help ensure that moms receive care beyond that period for serious health conditions, including cardiovascular disease, postpartum depression, and opioid use, and close a huge gap in women’s health coverage during a time in which the Centers for Disease Control and Prevention show one-third of preventable maternal deaths occur.

    "ACOG is very appreciative of House Energy and Commerce Chairman Frank Pallone and Ranking Member Greg Walden; Health Subcommittee Chairwoman Anna Eshoo and Ranking Member Michael Burgess, MD, FACOG; and Representatives Robin Kelly, Larry Bucshon, MD, Eliot Engel, and many more. It’s notable that the committee members are working across the aisle to deliver solutions to the nation’s maternal mortality crisis. We applaud their work and look forward to collaborating with all members of Congress to bring these bills to the floor of the House and Senate.”

    To learn more about recent state action to extend Medicaid coverage to pregnant women for a year after delivery, view ACOG’s map.

  • November 13, 2019 3:26 PM | Becca Liebers (Administrator)

    APAOG Member Benefits

    With over 250 members, the Association for Physician Assistants in Obstetrics and Gynecology is the only professional association devoted exclusively to PAs practicing in women's health. Established in 1991, APAOG is the collective voice for professionals working to improve the health care of women.

    APAOG commitment to its members:

    • To advocate for patient autonomy through education and collaborative care.
    • To promote clinical and academic excellence for members of APAOG.
    • To provide members with a forum to discuss topics that relate to PA's practicing in women's health.
    • To assist and support PA's and the healthcare team by providing information through education and programs relating to the delivery of quality women's healthcare services.

    Benefits of Membership 

    Download an APAOG Membership Flyer Here

    JOIN or Renew Today!
  • October 06, 2019 1:07 PM | Becca Liebers (Administrator)

    October 6-12, AAPA

    Every year from October 6-12, we celebrate National PA Week, which recognizes the PA profession and its contributions to the nation’s health.

    This week is also an opportunity to raise awareness and visibility of the profession. Before it was a week-long event, National PA Day was first celebrated on October 6, 1987, in honor of the 20th anniversary of the first graduating class of PAs from the Duke University PA program. October 6 is also the birthday of the profession’s founder, Eugene A. Stead, Jr., MD.

    More information here!

    Visit along on our facebook page

  • August 26, 2019 3:38 PM | Becca Liebers (Administrator)

    August 25, 2019 - MedPage Today

    Per the final two-part recommendation published at the USPSTF website and in JAMA, assessments for increased risk of BRCA1 and BRCA2 genetic mutations should be conducted in women who have a personal or family history of certain types of cancers (breast, ovarian, fallopian tube, or peritoneal cancers), or who have an ancestry associated with BRCA1 or BRCA2 mutations. Women found to be at increased risk should receive genetic counseling and, if indicated after counseling, BRCA testing. The first part of the recommendation received a 'B' grade, meaning a "high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial."

    Read More.

  • July 03, 2019 8:28 AM | Grant Dvorak (Administrator)

    July 3, 2019, Healthcare Business  

    Breast cancer is the second-most common cancer among women in the United States. Last year approximately 268,000 new cases of breast cancer were diagnosed in the U.S., and more than 40,000 women died of the disease. When breast cancer is found early, the five-year survival rate is 96%. If not identified until more advance stages (e.g., stage 4), the five-year survival rate drops to 16%. The key to survival is early detection.  

    Read more.

  • July 03, 2019 8:26 AM | Grant Dvorak (Administrator)

    July 3, 2019, MedPage Today 

    Updates to recommendations for hepatitis A and meningococcal vaccines were approved, while recommendations for the influenza vaccine remained unchanged, after the CDC's Advisory Committee for Immunization Practices (ACIP) meeting in Atlanta. Committee members also voted unanimously to leave the current recommendation for influenza vaccination as is. The annual influenza vaccine should continue to be offered to everyone 6 months or older who do not have contraindications. 

    Read more.

  • July 02, 2019 8:48 AM | Grant Dvorak (Administrator)

    July 2, 2019, MedPage Today 

    The appearance of simple ovarian cysts was common in premenopausal and postmenopausal women undergoing pelvic ultrasonography but was not associated with an increased risk of malignant ovarian cancer, researchers found. 

    Read more.

  • July 02, 2019 8:38 AM | Grant Dvorak (Administrator)

    July 2, 2019, MedPage Today 

    Breast density status should not be used as a stand-alone risk factor to refer women for supplemental imaging discussions, according to a new study. Instead, a combined approach using both breast density and Breast Cancer Surveillance Consortium (BCSC) 5-year risk score would identify those women at the highest risk for advanced cancer, said Karla Kerlikowske, MD, of the Department of Veterans Affairs in San Francisco, and colleagues.

    Read more.

  • July 01, 2019 12:46 PM | Grant Dvorak (Administrator)

    July 1, 2019, Pharmacy Times 

    Officials with the U.S. Food and Drug Administration have approved bevacizumab-bvzr (Zirabev, Pfizer), a biosimilar to bevacizumab (Avastin), for the treatment of five types of cancer, according to a press release. Bevacizumab-bvzr is indicated for the treatment of metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC); recurrent glioblastoma; metastatic renal cell carcinoma (RCC); and persistent, recurrent or metastatic cervical cancer. 

    Read more.

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 
Powered by Wild Apricot Membership Software